Workshop track 3 Workshop: Cardiovascular risk assessment from epidemiology to genetics| Volume 287, e8, August 2019

A Mendelian Randomization Analysis Of Lipoprotein(A) Lowering And Cardiovascular Risk Stratified By Ldl Cholesterol, Gender, And Antiplatelet Therapy: Implications For Clinical Outcome Trials

      Background and Aims: Lipoprotein(a) is causally associated with the risk of CVD. Novel therapies that potently and specifically reduce plasma concentration of lipoprotein(a) by up to 70−80% are currently in development. We sought to examine whether the effect of lipoprotein(a) lowering on risk of CVD is modified by LDL cholesterol (LDL-C) level, gender, and antiplatelet therapy to inform the design of clinical outcome trials.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect